Gensight Biologics SA launched a pair of phase III studies aimed at testing gene therapy candidate GS010's ability to preserve and restore vision in patients with blindness-causing Leber's hereditary optic neuropathy (LHON), a disease in which "time is of the essence," said Chairman and CEO Bernard Gilly.